The Company

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.

 

Aadi’s initial focus is the treatment of an ultra-rare cancer PEComa, also known as perivascular epithelioid cell tumor. 

Please check out Our Science and Pipeline for information about our work.